Katherine L Nathanson

Katherine L Nathanson's AcademicInfluence.com Rankings

Philosophy

#7653

World Rank

#10894

Historical Rank

Logic

#4699

World Rank

#6020

Historical Rank

philosophy Degrees

Katherine L Nathanson

Biology

#10336

World Rank

#13660

Historical Rank

Genetics

#1086

World Rank

#1185

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Katherine L Nathanson's Degrees

Doctorate Medicine University of Pennsylvania
PhD Genetics University of Pennsylvania

Why Is Katherine L Nathanson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Katherine L Nathanson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (2010) (1645)
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. (2010) (1228)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response (2017) (1109)
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations (2002) (860)
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (2017) (770)
Gene-panel sequencing and the prediction of breast-cancer risk. (2015) (747)
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. (2002) (726)
The tuberous sclerosis complex. (2006) (648)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006) (645)
Network modeling links breast cancer susceptibility and centrosome dysfunction. (2007) (628)
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. (1999) (570)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. (2006) (523)
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. (2011) (519)
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. (2017) (460)
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. (2008) (455)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma (2019) (382)
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. (2014) (359)
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer (2009) (336)
Breast cancer genetics: What we know and what we need (2001) (319)
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma (2014) (311)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas (2008) (299)
Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention (2014) (296)
ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes (2012) (286)
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. (2007) (276)
Counselling framework for moderate-penetrance cancer-susceptibility mutations (2016) (264)
Integrated Molecular Characterization of Testicular Germ Cell Tumors (2018) (261)
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia (2013) (253)
A Population-Based Study of Genes Previously Implicated in Breast Cancer. (2021) (250)
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
A Meta-Analysis Identifies New Loci Associated with Body Mass index in Individuals of African Ancestry (2013) (244)
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2008) (238)
Pheochromocytoma: the expanding genetic differential diagnosis. (2003) (237)
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel (2008) (230)
Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma (2011) (223)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade (2019) (214)
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. (2005) (208)
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers (2017) (202)
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. (2019) (196)
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. (2010) (196)
Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing (2013) (184)
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns (2010) (181)
HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses (2009) (180)
Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer (2011) (174)
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. (2012) (174)
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. (2013) (173)
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. (2000) (168)
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. (2016) (168)
Association of HPC2/ELAC2 genotypes and prostate cancer. (2000) (161)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) (2013) (157)
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma (2011) (156)
Meta-analysis identifies four new loci associated with testicular germ cell tumor (2013) (155)
Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood (2017) (155)
Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (154)
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target (2014) (149)
A genome wide linkage search for breast cancer susceptibility genes (2006) (146)
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. (2003) (146)
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. (2010) (145)
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores (2017) (142)
Biallelic TSC gene inactivation in tuberous sclerosis complex (2010) (140)
Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas (2014) (140)
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. (2013) (138)
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. (2008) (136)
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing (2016) (134)
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. (2011) (133)
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. (2006) (133)
Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer (2014) (129)
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2009) (124)
Hereditary kidney cancer syndromes. (2014) (123)
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. (2007) (123)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk (2013) (120)
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. (2007) (115)
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases (2009) (115)
PALB2 mutations in familial breast and pancreatic cancer (2011) (115)
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
Structural and functional division into two domains of the large (100- to 115-kDa) chains of the clathrin-associated protein complex AP-2. (1989) (111)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
Active Notch1 confers a transformed phenotype to primary human melanocytes. (2009) (110)
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. (2008) (108)
Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. (2016) (107)
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome (2011) (106)
"Other" breast cancer susceptibility genes: searching for more holy grail. (2001) (106)
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium (2002) (106)
Low penetrance genes associated with increased risk for breast cancer. (2000) (105)
Population Frequency of Germline BRCA1/2 Mutations. (2016) (104)
Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies (2015) (103)
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (103)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (103)
Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium (2017) (102)
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (2011) (101)
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. (2017) (100)
A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. (2013) (98)
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. (2008) (96)
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. (2000) (96)
Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk (2017) (96)
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (95)
Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor (2017) (94)
Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) (2018) (94)
Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor (2017) (94)
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation (2019) (93)
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes (2009) (93)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes (2008) (91)
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels (2007) (90)
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines (2014) (89)
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells (2013) (87)
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. (2002) (87)
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. (2001) (87)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (84)
Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood (2017) (82)
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (82)
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification (2019) (82)
Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2010) (77)
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. (2014) (75)
A genome-wide association study of breast cancer in women of African ancestry (2012) (74)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications (2005) (74)
Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. (2012) (72)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility (2014) (70)
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. (2000) (70)
Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. (2007) (69)
Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity. (2018) (67)
Shared heritability and functional enrichment across six solid cancers (2018) (67)
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. (2009) (65)
HIF- α effects on c-Myc distinguish two subtypes of sporadic VHL -deficient clear cell renal carcinoma (2009) (63)
Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. (2012) (63)
A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers (2006) (61)
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
Common breast cancer risk variants in the post-COGS era: a comprehensive review (2013) (60)
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. (2013) (60)
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. (2017) (59)
A comparison of DNA copy number profiling platforms. (2008) (59)
Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma (2006) (59)
Identification of intragenic deletions and duplication in the FLCN gene in Birt‐Hogg‐Dubé syndrome (2011) (58)
The molecular biology of renal cell carcinoma. (2013) (58)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer (2018) (57)
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2 (2009) (57)
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. (2011) (57)
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing (2011) (56)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2019) (55)
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
External Beam Radiation Therapy (EBRT) for Patients with Malignant Pheochromocytoma and Non-Head and -Neck Paraganglioma: Combination with 131I-MIBG (2012) (54)
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer (2019) (54)
Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. (2016) (54)
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling (2013) (54)
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers (2009) (53)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (53)
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2010) (53)
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. (2017) (51)
Risk of metachronous breast cancer after BRCA mutation–associated ovarian cancer (2013) (51)
Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood (2017) (50)
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy (2012) (50)
Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing (2015) (49)
Uncommon Filaggrin Variants Are Associated with Persistent Atopic Dermatitis in African Americans. (2018) (48)
Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy (2008) (48)
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG) (2020) (48)
Immunotherapy at Large: The road to personalized cancer vaccines (2013) (48)
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2 (2021) (48)
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2012) (47)
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. (2010) (46)
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. (2002) (46)
CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing (2017) (46)
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22 (2000) (45)
Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. (1999) (43)
A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development (2017) (43)
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. (2011) (42)
Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. (2020) (42)
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration (2013) (41)
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence (2009) (41)
The APC I1307K allele and breast cancer risk (1998) (41)
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib (2009) (40)
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2020) (40)
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (39)
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. (2009) (39)
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors (2008) (39)
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors (2019) (39)
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. (2016) (39)
Genomic Biomarkers for Breast Cancer Risk. (2016) (38)
Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. (2018) (38)
Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer (2007) (38)
Distinct MHC gene expression patterns during progression of melanoma (2009) (38)
Evolution of delayed resistance to immunotherapy in a melanoma responder (2021) (37)
AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study (2007) (37)
Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers (2015) (37)
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 (2017) (37)
A functionally significant SNP in TP53 and breast cancer risk in African-American women (2017) (36)
Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry (2018) (35)
SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. (2017) (35)
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma (2015) (34)
Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. (2010) (34)
Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. (2014) (33)
Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma (2014) (33)
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. (2016) (33)
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. (2019) (33)
Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma‐derived cell lines (2009) (33)
Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib (2014) (33)
Therapeutic approaches for women predisposed to breast cancer. (2011) (33)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
Predisposition alleles for Testicular Germ Cell Tumour. (2010) (31)
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers (2010) (31)
Publisher correction: Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 (2018) (31)
The FBXO4 Tumor Suppressor Functions as a Barrier to BrafV600E-Dependent Metastatic Melanoma (2013) (31)
Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis. (2019) (31)
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study (2012) (31)
Application of Panel-Based Tests for Inherited Risk of Cancer. (2017) (30)
Inherited susceptibility for pediatric cancer. (2005) (30)
Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome (2020) (29)
Multiple Vascular and Bowel Ruptures in an Adolescent Male with Sporadic Ehlers-Danlos Syndrome Type IV (1999) (28)
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) (2009) (28)
Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation inBRCA1, BRCA2orPALB2 (2019) (28)
Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry (2016) (28)
Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. (2013) (28)
Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic (2006) (27)
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. (2020) (27)
Variants in CHEK 2 Other than 1100 delC Do Not Make a Major Contribution to Breast Cancer Susceptibility (2003) (27)
The CHD8 overgrowth syndrome: A detailed evaluation of an emerging overgrowth phenotype in 27 patients (2019) (27)
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score (2021) (26)
Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. (2019) (26)
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma (2018) (25)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (2017) (25)
Genetic changes associated with testicular cancer susceptibility. (2016) (25)
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers (2009) (25)
Comparison of address-based sampling and random-digit dialing methods for recruiting young men as controls in a case-control study of testicular cancer susceptibility. (2013) (24)
An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women (2005) (22)
Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. (2021) (22)
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry (2019) (22)
The von Hippel–Lindau (VHL) germline mutation V84L manifests as early‐onset bilateral pheochromocytoma (2006) (22)
The APCI1307K allele and breast cancer risk. (1998) (22)
Molecular Testing in Melanoma (2012) (21)
Exploring the link between MORF4L1 and risk of breast cancer (2011) (21)
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
Hybrid peripheral nerve sheath tumor. (2012) (20)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (20)
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. (2019) (20)
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603 (2015) (19)
Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening? (2009) (19)
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers (2011) (19)
CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature (2016) (19)
Younger age-at-diagnosis for familial malignant testicular germ cell tumor (2009) (18)
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. (2009) (18)
Intestinal perforation in Ehlers-Danlos syndrome after enema treatment for constipation. (1998) (18)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
A Comparison of DNA Copy Number Profiling Platforms (2007) (18)
Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry (2017) (18)
Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers (2011) (18)
Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. (2020) (18)
Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative (2020) (18)
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3 (2015) (17)
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (17)
Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. (2019) (17)
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. (2006) (17)
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma (2016) (17)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry (2012) (16)
Association of HLA-DRB1 genetic variants with the persistence of atopic dermatitis. (2015) (16)
Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers (2004) (16)
Research participants’ experiences with return of genetic research results and preferences for web‐based alternatives (2019) (16)
International cancer seminars: a focus on kidney cancer. (2016) (16)
Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers (2011) (16)
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status (2020) (16)
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. (2020) (15)
PIM kinases as therapeutic targets against advanced melanoma (2016) (15)
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
A practical approach to adjusting for population stratification in genome-wide association studies: principal components and propensity scores (PCAPS) (2018) (15)
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models (2021) (15)
Rare inactivating PDE11A variants associated with testicular germ cell tumors. (2015) (14)
Common Genetic Variants and Modification of Penetrance of BRCA 2-Associated Breast Cancer (2010) (14)
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 (2012) (14)
No evidence that GATA3 rs570613 SNP modifies breast cancer risk (2009) (13)
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors (2015) (13)
Identification of 22 susceptibility loci associated with testicular germ cell tumors (2021) (13)
Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF) (2012) (13)
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers (2009) (13)
Thymic Stromal Lymphopoietin and IL7R Variants are Associated with Persistent Atopic Dermatitis. (2020) (13)
Enhancing the evaluation of PI3K inhibitors through 3D melanoma models (2016) (13)
Germ-line DICER1 mutations do not make a major contribution to the etiology of familial testicular germ cell tumours (2013) (13)
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2 (2011) (13)
Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. (2018) (13)
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
Taking the guesswork out of uveal melanoma. (2010) (12)
Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer (2014) (12)
Somatic genetics of testicular cancer in relationship to prognosis (2004) (12)
Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. (2021) (12)
Association between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistence (2019) (12)
Filaggrin sequencing and bioinformatics tools (2019) (12)
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women (2021) (12)
A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy. (2019) (11)
Germline POT1 Variants Can Predispose to Myeloid and Lymphoid Neoplasms (2021) (11)
Tumor Detection Rates in Screening of Individuals with SDHx-related Hereditary Paraganglioma-Pheochromocytoma Syndrome (2020) (11)
A human breast atlas integrating single-cell proteomics and transcriptomics. (2022) (11)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibility (2018) (11)
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers (2012) (10)
Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. (2021) (10)
AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study (2007) (10)
Genetic Susceptibility to Type 2 Diabetes and Breast Cancer Risk in Women of European and African Ancestry (2012) (10)
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women (2021) (10)
In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma (2019) (10)
Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores (2021) (9)
A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers (2020) (9)
Abstract 5111: Integrative phospho-proteomic and genomic analyses identify AXL as a potential biomarker and therapeutic target for NRAS-mutated melanoma (2011) (9)
Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast (2021) (9)
Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium (2018) (9)
Exploring the link between MORF4L1 and risk of breast cancer (2011) (8)
Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening. (2019) (8)
Tissue resources for clinical use and marker studies in melanoma. (2014) (8)
Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice (2016) (8)
Reframing the Biological Basis of Neuroprotection Using Functional Genomics: Differentially Weighted, Time-Dependent Multifactor Pathogenesis of Human Ischemic Brain Damage (2018) (7)
Correlation between plasma catecholamines, weight, and diabetes in pheochromocytoma and paraganglioma. (2021) (7)
Abstract GS2-01: Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study (2019) (7)
Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression (2021) (7)
Testicular germ cell tumor susceptibility associated with the UCK 2 locus on chromosome 1 q 23 (2013) (7)
Association of breast cancer risk and the mTOR pathway in women of African ancestry in ‘The Root’ Consortium (2017) (7)
Prevalence of mutations in a panel of breast cancer susceptibility genes in patients with early onset breast cancer. (2014) (7)
Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes (2011) (7)
Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants (2021) (7)
I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer. (1999) (6)
Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank (2021) (6)
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers (2012) (6)
Sequence of the rat αc large chain of the clathrin associated protein complex AP-2 (1990) (6)
Lower abdominal and pelvic radiation and testicular germ cell tumor risk (2020) (6)
Genetic Variation in IGF 2 and HTRA 1 and Breast Cancer Risk among BRCA 1 and BRCA 2 Carriers (2011) (6)
ALLELE-SPECIFIC COPY NUMBER ESTIMATION BY WHOLE EXOME SEQUENCING. (2017) (6)
Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry (2018) (6)
Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of Disease. (2017) (6)
Diagnosis of adult hereditary pulmonary disease and the role of genetic testing. (2010) (6)
Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma (2008) (6)
Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. (2020) (5)
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations (2016) (5)
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (5)
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. (2020) (5)
Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent. (2018) (5)
Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). (2014) (5)
Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers (2010) (5)
Accrual of Black participants to cancer clinical trials following a five-year prospective initiative of community outreach and engagement. (2021) (5)
Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model. (2019) (4)
Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors (2015) (4)
NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib (2019) (4)
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. (2007) (4)
A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy. (2018) (4)
Deletion of 15q11.2–15q13.1 in isolated human hemimegalencephaly (2009) (4)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (2018) (4)
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement (2021) (4)
Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry (2017) (4)
Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (4)
Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes (2016) (4)
A Recurrent ERCC 3 Truncating Mutation Confers Moderate Risk for Breast Cancer (2016) (4)
Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer. (2015) (4)
An intronic variant in PTEN is not associated with prostate cancer risk. (2001) (4)
Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing. (2015) (3)
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer (2020) (3)
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 (2023) (3)
Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel (2013) (3)
Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. (2021) (3)
Impact of integrating genomic data into the electronic health record on genetics care delivery. (2022) (3)
Genome-wide association studies in women of African ancestry identified 3 q 26 . 21 as a novel susceptibility locus for oestrogen receptor negative breast cancer (2017) (3)
Fine mapping thymic stromal lymphopoietin confirms association with rs1898671 and atopic dermatitis onset and persistence. (2019) (3)
Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) (2018) (3)
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. (2020) (3)
The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population (2022) (3)
HNPCC-associated pheochromocytoma: expanding the tumor spectrum. (2015) (2)
Retrospective, correlative study of BRAF mutation V600E in testicular cancer patients. (2013) (2)
Using a Machine Learning Approach to Identify Low-Frequency and Rare FLG Alleles Associated with Remission of Atopic Dermatitis (2021) (2)
Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer. (2015) (2)
Rare inactivating PDE 11 A variants associated with testicular germ cell tumors (2015) (2)
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy (2010) (2)
Sequence of the rat alpha c large chain of the clathrin associated protein complex AP-2. (1990) (2)
Sensitivity of clinical BRCA1 testing compared with linkage analysis. (2012) (2)
Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study (2021) (2)
Abstract 2990: Evidence for diverse mechanisms of tumorigenesis in breast and ovarian tumors of BRCA1/2 carriers (2015) (2)
Uncommon variants in FLG2 and TCHHL1 are associated with remission of atopic dermatitis in a large longitudinal US cohort (2022) (2)
Association study between polymorphisms in DNA methylation-related genes and testicular germ cell tumor risk. (2022) (2)
BRCA 1 and BRCA 2 Mutations in Breast Cancer Families with Multiple Primary Cancers 1 (2000) (2)
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
Abstract PD3-01: Population-based breast cancer risk estimates for predisposition gene mutations: Results from the CARRIERS study (2020) (2)
PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer (2022) (2)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
Resolving ATM haplotypes in whites. (2003) (1)
Abstract 4169: Population-based breast cancer risk estimates associated with cancer predisposition gene mutations from 32,298 breast cancer patients and 31,869 matched unaffected controls from the CARRIERS study (2019) (1)
Abstract 4511: Characterization of tumor neoantigen repertoire in patients with germline BRCA1/2 mutations (2016) (1)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
Epigenetic age acceleration in U.S. testicular cancer survivors (TCS). (2022) (1)
Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk (2021) (1)
Chapter 14: Hereditary Renal Cancer Syndromes (2016) (1)
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (1)
NRAS and BRAF mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib. (2013) (1)
Common breast cancer risk variants in the post-COGS era: a comprehensive review (2013) (1)
Tumor detection rates in screening carriers with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome based on prior tumor history. (2020) (1)
Abstract 659: Overexpression of TPX2 accelerates cell cycle progression in melanoma and is an indicator of response to Aurora A kinase inhibitors (2010) (1)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
Abstracts for the Second International Symposium on Central Nervous System Germ Cell Tumors (2005) (1)
Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. (2017) (1)
Genomic Assessment of Renal Cancer (2015) (1)
Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer. (2023) (1)
Diagnostic radiation and testicular germ cell tumor risk. (2018) (1)
Association of COMT and TPMT with treatment failure (TF), neuropathy (NTOX), and ototoxicity (OTOX) in patients with testicular cancer (TC) after cisplatin-based chemotherapy (CBCT). (2011) (1)
Inherited defects in checkpoint kinase 2 (CHEK2) to confer increased susceptibility to testicular germ cell tumors. (2018) (1)
Abstract 1291: High and moderate penetrance germline mutations in a number of genes are responsible for a small proportion of familial breast cancer risk in BRCAx families (2014) (1)
Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (1)
Abstract B11: Replication of previously identified breast cancer susceptibility loci in a breast cancer case-control study on women of African ancestry (2014) (1)
Characteristics of ductal carcinoma in situ found in BRCA1 and BRCA2 mutation carriers (2012) (1)
From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. (2021) (1)
Abstract P6-07-05: Mutational spectrum and tumor response in metastatic breast cancer (2016) (1)
HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a. (2014) (1)
Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers (2015) (1)
Abstract 4371: Integrated molecular characterization of pheochromocytoma and paraganglioma including a novel, recurrent and prognostic fusion gene (2016) (1)
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (1)
The BRCA founder outreach study: Initial results of a digital health model. (2020) (1)
Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma–pheochromocytoma syndrome (2020) (1)
Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers (2011) (1)
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
Abstract 4835: Targeting the ATR/CHK1 axis in combination with PARP inhibition is more effective than PARP inhibition alone in BRCA mutant models (2016) (1)
Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer. (2015) (1)
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration (2013) (1)
Molecular Diagnostics and Tumor Mutational Analysis (2015) (1)
Breast Cancer Risk and 6 q 22 . 33 : Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA 1 / 2 (2012) (1)
Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis (2014) (1)
Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. (2016) (1)
Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing. (2016) (1)
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells (2022) (1)
Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial (2012) (1)
Contralateral prophylactic mastectomy in affected carriers of deleterious BRCA1 or BRCA2 mutations: Does timing of genetic testing matter? (2006) (1)
Abstract LB-425: Replication of 18 susceptibility loci of breast cancer in women of African ancestry (2011) (1)
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers (2021) (1)
Abstract 2500: Copy number variation in recurrent BRCA1/2 germline mutation-associated breast and ovarian cancers (2020) (0)
TPX2 in melanoma: honing on drivers of amplification on chromosome 20q11.2 (2008) (0)
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | NOVA. The University of Newcastle's Digital Repository (2014) (0)
Abstract P5-09-02: Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora (2017) (0)
Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer (2022) (0)
Customizing the electronic health record for delivery of pharmacogenetics (2023) (0)
Table of Contents, Volume 175C, Number 2, June 2017 (2017) (0)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
Bilateral pneumothoraces, cystic lung disease and papular skin lesions in a young man (2009) (0)
Abstract 2280: Targeted massively parallel sequencing identifies a limited number of clinically actionable variants in women with early onset breast cancer. (2013) (0)
Abstract 1183: Mutation type and location in breast cancer susceptibility genes are associated with differential risk in the general population (2023) (0)
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (2018) (0)
Abstract 2622: SNP markers in theFGF9andMAP3K1region associate with testicular germ cell tumor susceptibility (2012) (0)
Abstract A02: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers (2016) (0)
LB727 Using a machine learning approach to identify rare and low-frequency filaggrin variants associated with remission of Atopic Dermatitis (2021) (0)
Abstract 5220: Evaluation of ACMG guideline classified variants in 180 cancer and incidental non-cancer genes in families with breast/ovarian cancer (2016) (0)
ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers (2010) (0)
Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway. (2017) (0)
Abstract 843: Imputation and meta-analysis of five genome-wide association studies identify multiple new loci associated with testicular germ cell tumor (2015) (0)
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy. (2015) (0)
Abstract 1203: Identification of 22 novel loci associated with susceptibility to testicular germ cell tumors (2020) (0)
Pathologic predictors of BRCA1/ BRCA2 (B1/B2) mutations in African-American (AA) women with early-onset breast cancer (BC) (2016) (0)
Follow-up MRI screening of BRCA1/2 mutation carriers (2008) (0)
A look back: Results from 1 year of routine clinical testing of both hematologic and solid tumors using two targeted next-generation sequencing (NGS) panels. (2014) (0)
Breast cancer risks in individuals testing negative for known family mutations in BRCA1 or BRCA2. (2016) (0)
Abstract PD3-02: Polygenic risk scores provide clinically meaningful risk stratification among women carrying moderate penetrance pathogenic variants in breast cancer predisposition genes: Results from the CARRIERS study (2020) (0)
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603 (2015) (0)
Rare Causes of Inherited Breast Cancer Susceptibility (2007) (0)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
Abstract 4663: Identification of germline variants in cancer susceptibility genes in patients with multiple primary cancers (2015) (0)
Risk of pediatric malignancy in families known to carry BRCA1/2 mutations. (2018) (0)
Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms (2020) (0)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Abstract 4648: How inherited mutations affect single cells within the tumor microenvironment in breast tumors stratified by receptor status (2023) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
Molecular and Cellular Pathobiology Integrative Genomic Analyses of Sporadic Clear Cell Renal Cell Carcinoma De fi ne Disease Subtypes and Potential New Therapeutic Targets (2011) (0)
Couch Care and Prevention Setting Paradigms in Personalized Cancer BRCA : Two Decades After (2014) (0)
Abstract 5092: Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma (2011) (0)
Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry (2020) (0)
Combining genetic analyses and pre-clinical studies in melanoma defines multiple sub-populations with differential responses to targeted therapies (2008) (0)
Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas (2023) (0)
Germline pathogenic variants in cancer predisposition genes among women with invasive lobular cancer of breast. (2021) (0)
Genetic risk assessment for hereditary RCC: Report from the consensus panel meeting. (2020) (0)
Chapter 2 Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors (2018) (0)
Association of GSTP1, COMT, and TPMT with testicular cancer (TC) treatment outcome after cisplatin-based chemotherapy (CBCT). (2012) (0)
Shared heritability and functional enrichment across six solid cancers (2019) (0)
The mutational spectrum of breast and ovarian tumors from BRCA1 and BRCA2 mutation carriers. (2013) (0)
Abstract 346: Integrative genomic analysis of sporadic clear cell renal cell carcinoma (2011) (0)
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG) (2020) (0)
Miniatures Immune Activation and a 9-Year Ongoing Complete Remission Following CD 40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma (2014) (0)
Tumor Regression When Combined with Docetaxel ( ARRY-142886 ) Induces Growth Arrest in Melanoma Cells Signal-Regulated Kinase Kinase Inhibitor AZD 6244 The Mitogen-Activated Protein / Extracellular (2007) (0)
Abstract 2684: Identification of 14 novel genetic loci for testicular germ cell tumor susceptibility (2019) (0)
Somatic genetic changes in association with testicular germ cell tumor prognosis. (2004) (0)
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3 (2015) (0)
University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch, (2013) (0)
Abstract A22: Homologous recombination deficiency negatively predicts for immune infiltration and antitumor immune activity in breast tumors with BRCA1/2 alterations (2018) (0)
Abstract 4251: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with somatic homologous recombination gene mutations (2015) (0)
Abstract 933: Copy number changes are associated withBRAFandNRASmutations and response to treatment with carboplatin, paclitaxel and sorafenib (2014) (0)
Recent 'advances' in breast and ovarian cancer genetics (2016) (0)
Mo1404 PREVALENCE OF PATHOGENIC GERMLINE VARIANTS IN CANCER-RISK GENES IN HEPATOCELLULAR CARCINOMA (2020) (0)
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. (2023) (0)
Abstract 2378: Harmonization of next generation sequencing data within consortia for gene discovery in familial breast cancer (2014) (0)
Childhood cancer in families with and without germline BRCA1/2 mutations ascertained at a high-risk breast cancer clinic. (2006) (0)
Abstract 711: Understanding the mechanisms of resistance to BRAF inhibitors in melanoma (2011) (0)
Abstract 4610: Functional characterization of a multicancer risk locus on chr5p15.33 reveals regulation ofTERTby ZNF148 (2015) (0)
Abstract 3892: Somatic genetic profiling in pheochromocytomas and paragangliomas (2015) (0)
Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas (2012) (0)
Determination of cancer susceptibility in probands with breast and ovarian cancer (2014) (0)
Association of GSTP1, COMT, and TPMT with testicular cancer (TC) treatment outcome after cisplatin-based chemotherapy (CBCT). (2012) (0)
Abstract 4177: The joint effects of polygenic risk scores and pathogenic variants in cancer predisposition genes on breast cancer risk in the general population: results from the CARRIERS study (2019) (0)
ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma (2023) (0)
A Cost-Effectiveness Review of Genetic Testing of Paragangliomas (2023) (0)
Abstract 2606: Absence of association between common genetic polymorphisms in the TERT-CLPTM1L locus and breast cancer risk in women of African descent (2012) (0)
Abstract 810: The CARRIERS consortium: Establishing refined breast cancer risk estimates in known predisposition genes (2016) (0)
Abstract 3691: Analysis of germline BRCA1/2 mutation associated breast and ovarian tumors reveals distinct pathways of immunosuppression (2017) (0)
Genetic predisposition to breast cancer among African American women. (2019) (0)
Abstract A12: Analysis of tumor immunogenicity in germline BRCA1/2 mutation associated breast and ovarian cancers (2017) (0)
Abstract P5-09-04: Impact of premenopausal RRSO on breast cancer risk inBRCA1/2mutation carriers: Maximizing bias-reduction (2019) (0)
Other Hereditary Breast Cancer Syndromes and Genes (2009) (0)
CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing (2018) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Receptor Tyrosine Kinase Expression in BRCA Mutation Carriers: An Opportunity for Prevention of Invasive Breast Cancer (2014) (0)
Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry (2020) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Title Interplay between BRCA 1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer (2012) (0)
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (0)
Polygenic Risk Scores for Prediction of Breast Cancer Risk in Women of African Ancestry: a Cross-Ancestry Approach (2021) (0)
Cutaneous Hamartoneoplastic Disorders (2013) (0)
Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. (2020) (0)
Trends in and determinants of germline BRCA1/2 testing in patients with breast and ovarian cancer. (2022) (0)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
Hybridization Histology : Analyses Based on Array Comparative Genomic Cancer Cell Lines as Genetic Models of Their Parent Updated (2007) (0)
1177: Testicular Cancer Susceptidility and Variants in Androgen Metabolism Genes (2004) (0)
101 Uncommon alleles in FLG2 and TCHHL1 are associated with remission of atopic dermatitis (2021) (0)
Abstract 3282: Determination of cancer susceptibility in probands with breast and ovarian cancer (2014) (0)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (0)
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2022) (0)
q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
Abstract P2-09-01: Patient reported outcomes of multiplex breast cancer susceptibility testing utilizing a tiered-binned counseling and informed consent model in BRCA1/2 negative patients (2016) (0)
Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. (2016) (0)
It's Not You, It's Me: Somatic and Germline Mutations Detected Through Routine Clinical Testing (2016) (0)
microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603. (2014) (0)
Response to Hannah-Shmouni and Stratakis (2018) (0)
Abstract 1182: Patient derived xenograft (PDX) of human melanoma to predict clinical responses (2014) (0)
Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (0)
A functionally significant SNP in TP53 and breast cancer risk in African-American women (2017) (0)
HRDex: a tool for deriving homologous recombination deficiency (HRD) scores from whole exome sequencing data (2022) (0)
Response to Hannah-Shmouni and Stratakis (2018) (0)
Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes (2022) (0)
A genome-wide association study of breast cancer in women of African ancestry (2012) (0)
Abstract P4-12-33: Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome (2020) (0)
Molecular Genetics of Testicular Germ Cell Tumor (2010) (0)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
First international workshop of the ATM and cancer risk group (4-5 December 2019) (2021) (0)
Abstract 1352: Genetic susceptibility to immune-related adverse events among melanoma patients treated with ipilimumab (2021) (0)
Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes (2017) (0)
Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization (2016) (0)
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers (2017) (0)
Germ-line DICER1 mutations do not make a major contribution to the etiology of familial testicular germ cell tumours (2013) (0)
MP41-18 CLINICAL MANIFESTATIONS OF BIRT-HOGG-DUBE SYNDROME IN A LARGE CLINICAL COHORT (2023) (0)
Abstract A003: Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes (2022) (0)
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (2017) (0)
Abstract 4668: Targeted, massively parallel sequencing identifies novel genetic subsets of cutaneous melanoma (2015) (0)
Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response (2016) (0)
Inherited mutations in breast cancer patients with and without multiple primary cancers. (2018) (0)
Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression (2016) (0)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma (2019) (0)
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects (2022) (0)
Male breast cancer in BRCA1 and BRCA2 mutation carriers (2018) (0)
Clinical and molecular characteristics of NF1 mutations identified on hereditary cancer multi-gene panels. (2018) (0)
The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib. (2023) (0)
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood (2022) (0)
Abstract 2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target (2015) (0)
Abstract 1682: Non-V600 BRAF mutants in melanoma: Multiple MAPK mutations and distinctive RNA expression (2019) (0)
Abstract P5-10-04: Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort (2017) (0)
A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib. (2022) (0)
Interest in and outcomes with web-based education for return of genetic research results for inherited susceptibility to breast cancer. (2018) (0)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
Abstract 796: ERCC3 R109X is a moderate risk breast cancer risk variant in Ashkenazi Jews (2016) (0)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (0)
Abstract 1312: Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry in the ROOT Consortium (2017) (0)
Abstract 2723: How BRCA1/2 mutations in TNBC affect TME and subsequently immune cell functions (2021) (0)
SNP rs2180341 per-allele hazard ratios (HRs) and 95% confidence intervals (CIs) among Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) in A. BRCA1 mutation carriers B. BRCA2 mutation carriers. (2012) (0)
EMR documentation of genetics evaluations in patients with ovarian cancer. (2019) (0)
Identifying Somatic Genetic Changes in Prostate Cancer (2005) (0)
Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry (2016) (0)
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma Graphical (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Katherine L Nathanson?

Katherine L Nathanson is affiliated with the following schools:

Medical University of Vienna
Autonomous University of Barcelona
Wayne State University
University of Ibadan
University of Cambridge
Harvard University
University of Pennsylvania

Katherine L Nathanson's Academic­Influence.com Rankings

Katherine L Nathanson's Degrees

Why Is Katherine L Nathanson Influential?

Katherine L Nathanson's Published Works

Published Works

What Schools Are Affiliated With Katherine L Nathanson?

Katherine L Nathanson's AcademicInfluence.com Rankings